Telitacicept in refractory juvenile generalized myasthenia gravis: a case report and collective analysis - Takeaways - MDSpire

Telitacicept in refractory juvenile generalized myasthenia gravis: a case report and collective analysis

  • By

  • Yanhong Sun

  • Guiling Liu

  • Hongwei Zhang

  • Kai Ma

  • June 8, 2026

  • 0 min

Share

  • 1

    Telitacicept is a dual inhibitor of BAFF and APRIL, showing efficacy in adult generalized myasthenia gravis (gMG) but limited data in pediatric cases.

  • 2

    In a case study, an 11-year-old female with refractory gMG showed significant improvement in MG-ADL and QMG scores after 12 weeks of telitacicept treatment.

  • 3

    The patient experienced a 41.6% reduction in corticosteroid dose by week 32, indicating a potential corticosteroid-sparing effect of telitacicept.

  • 4

    Collective analysis of four pediatric cases revealed marked improvement in three patients at three months, with sustained clinical improvement by five to six months.

  • 5

    No severe adverse events were reported in the cases reviewed, suggesting that telitacicept may be well-tolerated in juvenile refractory gMG.

Original Source(s)

Telitacicept in refractory juvenile generalized myasthenia gravis: a case report and collective analysis

  • by Yanhong Sun, Guiling Liu, Hongwei Zhang, Kai Ma

  • June 8, 2026

Related Content

Perampanel use in pediatric autoimmune encephalitis-related seizures and epilepsy: a retrospective case series

Early ICU Rehab Backed, With Caveats

Invited narrative review supports early, interprofessional rehabilitation across the ICU recovery continuum while emphasizing heterogeneous evidence and inconsistent implementation worldwide.

Effects of trampoline training on lower-limb strength and balance in children and adolescents with special needs: a multilevel systematic review and meta-analysis